サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1387442

肢端紅痛症治療市場レポート：2030年までの動向、予測、競合分析

Erythromelagia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日
発行
Lucintel
ページ情報
英文 150 Pages
納期
3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

肢端紅痛症治療市場レポート：2030年までの動向、予測、競合分析
出版日: 2023年11月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肢端紅痛症治療の動向と予測

世界の肢端紅痛症治療市場は、2024年から2030年にかけてCAGR 5.8％で成長すると予測されます。この市場の主な促進要因は、赤芽球癆患者の増加、精密医療への投資の高まり、創薬技術の進歩です。世界の肢端紅痛症治療市場の将来は、病院、在宅医療、専門クリニックの各市場における機会によって有望視されています。

肢端紅痛症治療市場の洞察

Lucintelの予測によると、予測期間中、赤芽球癆の症状管理に有効な薬剤が入手しやすいことから、薬物療法が引き続き大きなセグメントを占める。

赤芽球癆の患者に包括的な治療を提供するためのインフラと専門知識の必要性が高まっているため、この市場の中では病院が最大のセグメントであり続けると思われます。

北米は、研究大学、医学部、製薬会社の数が増加しているため、予測期間中も最大の地域です。

本レポートでは、以下の11の主要な質問に回答している：

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
  • Q.2.どのセグメントがより速いペースで成長するのか、またその理由は？
  • Q.3.今後成長が加速すると思われる地域とその理由は？
  • Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
  • Q.5.この市場におけるビジネスリスクと競合の脅威は？
  • Q.6.この市場における新たな動向とその理由は？
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は？
  • Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界の肢端紅痛症治療市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界の肢端紅痛症治療市場動向（2018～2023年）と予測（2024～2030年）
  • 治療別の世界の肢端紅痛症治療市場
    • 薬剤
    • 手術
  • タイプ別の世界の肢端紅痛症治療市場
    • 原発性紅斑痛症
    • 続発性紅斑痛症
  • 薬剤別の世界の肢端紅痛症治療市場
    • リドカイン
    • カプサイシン
    • ジクロフェナク
    • ブリモニジン
    • ミソプロストール
    • その他
  • 最終用途別の世界の肢端紅痛症治療市場
    • 病院
    • ホームケア
    • 専門クリニック
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の肢端紅痛症治療市場
  • 北米の肢端紅痛症治療市場
  • 欧州の肢端紅痛症治療市場
  • アジア太平洋肢端紅痛症治療市場
  • その他地域肢端紅痛症治療市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 治療別の世界の肢端紅痛症治療市場の成長機会
    • タイプ別の世界の肢端紅痛症治療市場の成長機会
    • 薬剤別の世界の肢端紅痛症治療市場の成長機会
    • 最終用途別の世界の肢端紅痛症治療市場の成長機会
    • 地域別の世界の肢端紅痛症治療市場の成長機会
  • 世界の肢端紅痛症治療市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の肢端紅痛症治療市場の能力拡大
    • 世界の肢端紅痛症治療市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Teva Pharmaceutical Industries
  • Xenon
  • Biogen
  • ICAGEN
  • Pfizer
  • Zydus Cadila
  • ANI Pharmaceuticals
目次

Erythromelagia Treatment Trends and Forecast

The future of the global erythromelagia treatment market looks promising with opportunities in the hospital, homecare, and specialty clinic markets. The global erythromelagia treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are growing number of patients with erythromelalgia, rising investment in precision medicine, and advancement in drug discovery technologies.

A more than 150-page report is developed to help in your business decisions.

Erythromelagia Treatment by Segment

The study includes a forecast for the global erythromelagia treatment by treatment, type, drug, end-use, and region.

Erythromelagia Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Medication
  • Surgery

Erythromelagia Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Primary Erythromelalgia
  • Secondary Erythromelalgia

Erythromelagia Treatment Market by Drug [Shipment Analysis by Value from 2018 to 2030]:

  • Lidocaine
  • Capsaicin
  • Diclofenac
  • Brimonidine
  • Misoprostol
  • Others

Erythromelagia Treatment Market by End-Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Erythromelagia Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Erythromelagia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies erythromelagia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the erythromelagia treatment companies profiled in this report include-

  • Teva Pharmaceutical Industries
  • Xenon
  • Biogen
  • ICAGEN
  • Pfizer
  • Zydus Cadila
  • ANI Pharmaceuticals

Erythromelagia Treatment Market Insights

Lucintel forecasts that medication will remain the larger segment over the forecast period due to availablilty of medications, which are effective in managing the symptoms of the disease.

Within this market, hospital will remain the largest segment due to growing need of infrastructure and expertise to provide comprehensive care for patients with erythromelalgia.

North America will remain the largest region over the forecast period due to rising number of research universities, medical schools, and pharmaceutical firms in the region.

Features of the Global Erythromelagia Treatment Market

Market Size Estimates: Erythromelagia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Erythromelagia treatment market size by various segments, such as by treatment, type, drug, end-use, and region in terms of value ($B).

Regional Analysis: Erythromelagia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatments, types, drugs, end-uses, and regions for the erythromelagia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the erythromelagia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for erythromelagia treatment market?

Answer: The global erythromelagia treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the erythromelagia treatment market?

Answer: The major drivers for this market are growing number of patients with erythromelalgia, rising investment in precision medicine and advancement in drug discovery technologies.

Q3. What are the major segments for erythromelagia treatment market?

Answer: The future of the erythromelagia treatment market looks promising with opportunities in the hospital, homecare, and specialty clinic markets.

Q4. Who are the key erythromelagia treatment market companies?

Answer: Some of the key erythromelagia treatment companies are as follows:

  • Teva Pharmaceutical Industries
  • Xenon
  • Biogen
  • ICAGEN
  • Pfizer
  • Zydus Cadila
  • ANI Pharmaceuticals

Q5. Which erythromelagia treatment market segment will be the largest in future?

Answer: Lucintel forecasts that medication will remain the larger segment over the forecast period due to availablilty of medications, which are effective in managing the symptoms of the disease.

Q6. In erythromelagia treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to rising number of research universities, medical schools, and pharmaceutical firms in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the erythromelagia treatment market by treatment (medication and surgery), type (primary erythromelalgia and secondary erythromelalgia), drug (lidocaine, capsaicin, diclofenac, brimonidine, misoprostol, and others), end-use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Erythromelagia Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Erythromelagia Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Erythromelagia Treatment Market by Treatment
    • 3.3.1: Medication
    • 3.3.2: Surgery
  • 3.4: Global Erythromelagia Treatment Market by Type
    • 3.4.1: Primary Erythromelalgia
    • 3.4.2: Secondary Erythromelalgia
  • 3.5: Global Erythromelagia Treatment Market by Drug
    • 3.5.1: Lidocaine
    • 3.5.2: Capsaicin
    • 3.5.3: Diclofenac
    • 3.5.4: Brimonidine
    • 3.5.5: Misoprostol
    • 3.5.6: Others
  • 3.6: Global Erythromelagia Treatment Market by End-Use
    • 3.6.1: Hospitals
    • 3.6.2: Homecare
    • 3.6.3: Specialty Clinics
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Erythromelagia Treatment Market by Region
  • 4.2: North American Erythromelagia Treatment Market
    • 4.2.2: North American Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.3: European Erythromelagia Treatment Market
    • 4.3.1: European Erythromelagia Treatment Market by Treatment: Medication and Surgery
    • 4.3.2: European Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.4: APAC Erythromelagia Treatment Market
    • 4.4.1: APAC Erythromelagia Treatment Market by Treatment: Medication and Surgery
    • 4.4.2: APAC Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.5: ROW Erythromelagia Treatment Market
    • 4.5.1: ROW Erythromelagia Treatment Market by Treatment: Medication and Surgery
    • 4.5.2: ROW Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Erythromelagia Treatment Market by Treatment
    • 6.1.2: Growth Opportunities for the Global Erythromelagia Treatment Market by Type
    • 6.1.3: Growth Opportunities for the Global Erythromelagia Treatment Market by Drug
    • 6.1.4: Growth Opportunities for the Global Erythromelagia Treatment Market by End-Use
    • 6.1.5: Growth Opportunities for the Global Erythromelagia Treatment Market by Region
  • 6.2: Emerging Trends in the Global Erythromelagia Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Erythromelagia Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Erythromelagia Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Teva Pharmaceutical Industries
  • 7.2: Xenon
  • 7.3: Biogen
  • 7.4: ICAGEN
  • 7.5: Pfizer
  • 7.6: Zydus Cadila
  • 7.7: ANI Pharmaceuticals